Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

Little-Known HOWL Stock Skyrockets 100% on Biotech Merger News

22 August 2026 · By · Wire by Fusion42

Published

22 August 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at finance.yahoo.com →

◆ Verified

Fusion42 · 22 August 2026 · Fusion42 review

Werewolf Therapeutics (HOWL) stock surged over 100% following the announcement of its merger with Ambros Therapeutics, gaining access to Ambros's late-stage treatment for Complex Regional Pain Syndrome Type 1 and securing $150 million in funding through an oversubscribed PIPE.

This Wire brief sits within Fusion42's coverage of Biotech.

◆ ◆ The Wire takeaway

Ambros's late-stage drug trial sets a clear milestone to watch, and you need to plan for the 2028 readout as a make-or-break sales event. Your merger aftermath will demand navigating dilution while pivoting to the new asset's clinical progress.

◆ Coverage

1 source · 22 Aug 2026

◆ Related on Wire

◆ Topics

Biotechbiotechmergerclinical-trialfundingpharma